A History Of Flip Flop Decisions Remains @ The Helm @ Radius Research the Interviewer hits the correct number of 150% Dilution with a capital raise of 10M USD. Then turns right around and says a capital raise of 10M USD through Algernon Neuro only requires roughly a 30% dilution of Algernon Neuro. That's fundamentally inaccurate. Moreau said they value Algernon Neuro at 20M USD. You can't raise 10M USD without diluting 50% (Half) of Algernon Neuro to would be "private" investors. Just because you say something over and over again doesn't make it less false. It would appear that the gaslighting never ends.
To date, you are funding the blitz of pump action to boost the private company and simultaneously being told you're likely better off investing in Algernon Neuro because Algernon Pharmaceuticals investors are basically incompetent. I'm of the belief there is enough of that to go around from top to bottom (Board of Directors/Retail Investors) in regards to all things Algernon Pharmaceuticals. You're now officially the stepchild here. Worse case scenario, Algernon Pharmaceuticals goes bust in the next couple few years. Hence, the push to get you to buy into the "private" company, managed by the same decision making people, before AlphaNorth figures out a way to buy up those shares as well, if not already
Speaking of past practice. It is the past practice of your leaders to pull the rug out from under you while claiming it's for your own good. Look back at what happened to your FAIMS agreement with the University of Florida. Moreau surrendered the agreement after years of financial partnership witheith Cannabix Technologies Inc. Algernon Pharmaceuticals footed 50% of the cost to push the FAIMS tech forward. If you look at Cannabix website they now tout a FAIMS device for researchers and the like to explore whatever their hearts desire. That is the exact same strategy Algernon Pharmaceuticals (formerly Breathtec Biomedical) was pursuing to not be in conflict with Cannabix's pursuit of controlled substances. In the end, Algernon Pharmaceuticals came away from that deal with absolutely nothing to show for its efforts alongside its sister company. Meanwhile, Cannabix Technologies walked away flush with cash on hand and at least 1,000,000 shares of Algernon Pharmaceuticals with sole pursuit of the University of Florida FAIMS agreement.
I see history repeating itself...and potentially headed for the final BIG CLIFF without positive data from a loooooong drawn out flip flop management "Decision" to pursue a standalone Chronic Cough study. A study which continues to have the strongest preclinical data of any angle in Algernon Pharmaceuticals pipeline. Yeah, five years into it Moreau now wants to know if Ifenprodil is a billion dollar drug based on Bellus Health doing their job for shareholders by getting after a sitting duck. It remains an answer everyone could have easily gotten back in 2021. Think of all the destructive dilution of the company they could have avoided had they not flip flopped throughout their leadership existence?